SCORE2 Report 2: Study Design and Baseline Characteristics.

[1]  T. Wisløff,et al.  Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) in a Norwegian population of patients with neovascular age-related macular degeneration compared to a control population , 2019, Health and Quality of Life Outcomes.

[2]  N. Eter,et al.  Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. , 2016, American journal of ophthalmology.

[3]  D. Călugăru,et al.  Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. , 2016, American journal of ophthalmology.

[4]  R. Hays,et al.  National Eye Institute Visual Function Questionnaire-25 , 2016 .

[5]  Jennifer K. Sun,et al.  Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. , 2015, The New England journal of medicine.

[6]  Y. Ogura,et al.  VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study , 2013, British Journal of Ophthalmology.

[7]  B. Doft,et al.  Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14. , 2012, Archives of ophthalmology.

[8]  J. Haller,et al.  Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. , 2012, Ophthalmology.

[9]  M. Stewart.  Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug , 2012, British Journal of Ophthalmology.

[10]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[11]  S. Seregard,et al.  Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin®) , 2010, Acta ophthalmologica.

[12]  M. Figueroa,et al.  Results of bevacizumab as the primary treatment for retinal vein occlusions , 2010, British Journal of Ophthalmology.

[13]  M. Maia,et al.  COMPARISON OF TWO DOSES OF INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION: Results of the Pan American Collaborative Retina Study Group at 24 Months , 2010, Retina.

[14]  M. Blumenkranz,et al.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. , 2010, Ophthalmology.

[15]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[16]  G. Staurenghi,et al.  Visual Improvement in Central Retinal Vein Occlusion (crvo) Following Intravitrel Injections of Bevacizumab , 2010 .

[17]  Tien Yin Wong,et al.  The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. , 2010, Ophthalmology.

[18]  K. Schaal,et al.  Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[19]  K. Bartz-Schmidt,et al.  Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results , 2010, International Ophthalmology.

[20]  Ingrid U Scott,et al.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. , 2009, Archives of ophthalmology.

[21]  Thomas Ach,et al.  Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[22]  U. Schmidt-Erfurth,et al.  Intravitreal bevacizumab (Avastin®) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial , 2008, British Journal of Ophthalmology.

[23]  Sander R. Dubovy,et al.  LONG-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR THE MANAGEMENT OF CENTRAL RETINAL VEIN OCCLUSION , 2008, Retina.

[24]  U. Schmidt-Erfurth,et al.  Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study , 2008, British Journal of Ophthalmology.

[25]  S. Priglinger,et al.  INTRAVITREAL BEVACIZUMAB INJECTIONS FOR TREATMENT OF CENTRAL RETINAL VEIN OCCLUSION: Six-Month Results of a Prospective Trial , 2007, Retina.

[26]  M. Leavitt,et al.  Department of Health and Human Services , 2007, Disaster Medicine and Public Health Preparedness.

[27]  Michael J. Pencina,et al.  Trends in the Incidence of Type 2 Diabetes Mellitus From the 1970s to the 1990s: The Framingham Heart Study , 2006, Circulation.

[28]  I. Hajjar,et al.  Hypertension: trends in prevalence, incidence, and control. , 2006, Annual review of public health.

[29]  J. Slakter,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF MACULAR EDEMA IN CENTRAL RETINAL VEIN OCCLUSION: A Short-Term Study , 2006, Retina.

[30]  E. Opremcak,et al.  RADIAL OPTIC NEUROTOMY FOR CENTRAL RETINAL VEIN OCCLUSION: 117 Consecutive Cases , 2006, Retina.

[31]  P. Sorlie,et al.  The Burden of Adult Hypertension in the United States 1999 to 2000: A Rising Tide , 2004, Hypertension.

[32]  M. Mandelcorn,et al.  INTERNAL LIMITING MEMBRANE PEELING FOR DECOMPRESSION OF MACULAR EDEMA IN RETINAL VEIN OCCLUSION: A REPORT OF 14 CASES , 2004, Retina.

[33]  L. Bynoe,et al.  RETINAL ENDOVASCULAR SURGERY FOR CENTRAL RETINAL VEIN OCCLUSION: Initial Experience of Four Surgeons , 2004, Retina.

[34]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[35]  M. Elman,et al.  Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. , 2003, Transactions of the American Ophthalmological Society.

[36]  M. Blumenkranz,et al.  Treatment of central retinal vein occlusion by vitrectomy with lysis of vitreopapillary and epipapillary adhesions, subretinal peripapillary tissue plasminogen activator injection, and photocoagulation. , 2002, American journal of ophthalmology.

[37]  M. Tsilimbaris,et al.  Lamina puncture: pars plana optic disc surgery for central retinal vein occlusion. , 2002, Archives of ophthalmology.

[38]  D L DeMets,et al.  Computations for group sequential boundaries using the Lan-DeMets spending function method. , 2000, Controlled clinical trials.

[39]  R. Hays,et al.  Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators , 1998 .

[40]  I. Constable,et al.  Laser-induced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: evaluation of the complications and their risk factors. , 1998, American journal of ophthalmology.

[41]  W J Shih,et al.  Modifying the design of ongoing trials without unblinding. , 1998, Statistics in medicine.

[42]  P. Mitchell,et al.  Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. , 1996, Archives of ophthalmology.

[43]  David J. Wilson,et al.  Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. , 1995, Ophthalmology.

[44]  G. Coscas,et al.  A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. , 1994, American journal of ophthalmology.

[45]  Y. Hochberg.  A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[46]  Wayne Smith,et al.  Prevalence and Associations of Retinal Vein Occlusion in Australia , 2017 .

[47]  D. Călugăru.  [Risk factors in central retinal vein occlusion]. , 2011, Oftalmologia.

[48]  R. Klein,et al.  The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. , 2000, Transactions of the American Ophthalmological Society.

[49]  Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. , 1997, Archives of ophthalmology.

[50]  Ditte J. Hess,et al.  A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. , 1995, Ophthalmology.

[51]  A. Hillis,et al.  Baseline and early natural history report. The Central Vein Occlusion Study. , 1993, Archives of ophthalmology.